INTRODUCTION: Critically ill patients with cirrhosis admitted to the intensive care unit (ICU) are usually on broad-spectrum antibiotics because of suspected infection or as a hospital protocol. It is unclear if additional rifaximin has any synergistic effect with broad-spectrum antibiotics in ICU patients with acute overt hepatic encephalopathy (HE). METHODS: In this double-blind trial, patients with overt HE admitted to ICU were randomized to receive antibiotics (ab) alone or antibiotics with rifaximin (ab + r). Resolution (or 2 grade reduction) of HE, time to resolution of HE, in-hospital mortality, nosocomial infection, and changes in endotoxin levels were compared between the 2 groups. A subgroup analysis of patients with decompensated cirrhosis and acute-on-chronic liver failure was performed. RESULTS: Baseline characteristics and severity scores were similar among both groups (92 in each group). Carbapenems and cephalosporin with beta-lactamase inhibitors were the most commonly used ab. On Kaplan-Meier analysis, 44.6% (41/92; 95% confidence interval [CI], 32–70.5) in ab-only arm and 46.7% (43/92; 95% CI, 33.8–63) in ab + r arm achieved the primary objective (P = 0.84).Time to achieve the primary objective (3.65 ± 1.82 days and 4.11 ± 2.01 days; P = 0.27) and in-hospital mortality were similar among both groups (62% vs 50%; P = 0.13). Seven percent and 13% in the ab and ab + r groups developed nosocomial infections (P = 0.21). Endotoxin levels were unaffected by rifaximin. Rifaximin led to lower in-hospital mortality (hazard ratio: 0.39 [95% CI, 0.2–0.76]) in patients with decompensated cirrhosis but not in patients with acute-on-chronic liver failure (hazard ratio: 0.99 [95% CI, 0.6–1.63]) because of reduced nosocomial infections. DISCUSSION: Reversal of overt HE in those on ab was comparable with those on ab + r.
Despite effective vaccination programs, waning immunity in the vaccinated populations and the emergence of variants of concern posed a risk of breakthrough infections. A booster dose was demonstrated to provide substantially increased protection against symptomatic disease and hospitalization. We aimed to evaluate immune memory and the efficacy of reducing the rate of SARS-CoV-2 infection post heterologous booster with CORBEVAX after primary vaccination with two doses of COVISHIELD. SARS-CoV-2 S1/S2 spike IgG and RBD-specific antibody responses were elicited with both booster vaccines, with a greater response in individuals receiving heterologous booster. T and B memory responses were increased with booster dose, whereas B memory needed a longer duration to develop in individuals who received a homologous booster (90 days) in comparison to a heterologous booster (30 days). RBD-specific B memory and antibody-secreting (non-memory) B lymphocytes were enhanced with both boosters; however, the duration of response was longer with the heterologous booster compared to the homologous, indicating greater protection with the heterologous booster. The rate of infection 14 days after administration of the heterologous booster was comparatively lower than that of the homologous booster, with the symptoms being much less or asymptomatic.
31 January 2023 in Critical Care Research and Practice
Background. Though vaccines have been reported as highly efficacious in preventing severe COVID‐19 disease, there is emerging data of severe infections, albeit a small number, in vaccinated individuals. We have conducted a retrospective observational study to assess the clinical characteristics, immunological response, and disease outcomes among the vaccinated and unvaccinated patients admitted to the ICU with severe COVID‐19 disease. Methods. Study Design and Participants. We conducted a retrospective observational study in COVID ICU of a tertiary care hospital. Data were collected from the month of 1 April 2021 to 31 November 2021. All adult patients admitted to the ICU having severe COVID‐19 disease were included in the study. Data were collected from the medical records database which included demographics, a clinical course in the ICU, laboratory and radiological parameters, and disease outcomes. In a subset of patients, cell‐mediated immunity and S1S2‐neutralising antibody assessment was done. Results. A total of 419 patients with severe COVID‐19 were included in the study. Of the 419 patients, 90 (21.5%) were vaccinated, and 329 (78.5%) were unvaccinated. There was a significantly higher mortality in unvaccinated severe COVID 19 patients as compared to vaccinated severe COVID patients (46.2% vs 34.4%; P < 0.0455). The neutralizing antibody titre was significantly higher in survivors as compared to nonsurvivors (2139.8, SE ± 713.3 vs 471, SE ± 154.4); P < 0.026. Conclusion. Our study suggests the association of lower neutralizing antibody levels with mortality in ICU patients admitted with COVID‐19 breakthrough infections.
Human Metapneumovirus (hMPV) is a paramyxovirus that was detected in India first in 2004. It causes a mild common cold in most cases but serious illness has been reported in some young children, adults >65 years and the immunocompromised. AIM: To study the age related prevalence of IgG antibodies in the population and also to determine the percent positivity and seasonal variation of hMPV infection. MATERIAL AND METHODS: This cross-sectional study assessed seroprevalence by testing 820 serum samples collected between January 25 th – 31 st 2025 for hMPV IgG antibodies by ELISA and stratified according to age and sex. hMPV PCR trends: Retrospective data from the 1276 tests for Respiratory Viruses done at our centre during 2023 and 2024 were analysed and comprised of age groups 0-18, 19-30 ,31-45, 45-60 and > 60 years. The relationship between gender (M/F) and outcome (positive/negative) across various age groups was analysed using the chi-square test for independence in Graph Pad Prism 8.0. RESULTS: Seroprevalence study: Overall hMPV IgG Antibody Positivity was 53.4%. Antibody positivity was higher in above 60 years when compared to other groups and was statistically significant (P=0.0001) and female predominance is seen. In hMPV PCR trends: A higher percentage of positivity were observed in > 60years individuals who had hospitalisation when compared to the other groups which was statistically significant(P=0.0001). Overall Percent positivity was 7.8% in 2023 and 3.8% in 2024. Seasonal peaks occurred in Feb-Mar and Oct. 92.6% of patients were discharged and doing well on follow-up and only 7.4% deaths were seen. CONCLUSION: Our findings highlight around 53.4% of the total study population had hMPV IgG antibodies. PCR positivity and antibody positivity was higher in individuals over 60 who had other comorbidities. Hospitalization and mortality rates are significantly high in this high risk groups. Vaccine development for high-risk individuals is recommended.
15 December 2021 in IP International Journal of Medical Paediatrics and Oncology
Fecal Calprotectin as early predictor for screening and relapse in pediatric chronic diarrhea in India - IJMPO- Print ISSN No: - 2581-4699 Online ISSN No:- 2581-4702 Article DOI No:- 10.18231/j.ijmpo.2021.036, IP International Journal of Medical Paediatrics and Oncology-IP Int J Med Paediatr Oncol
6 February 2023 in Journal of Laboratory Physicians
Introduction Vaccination has shown to be protective against severe coronavirus disease 2019 by various studies. However, the vaccine efficacy was demonstrated to be less against the emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Both vaccine- and infection-induced immunity against SARS-CoV-2 may prevent reinfection and severity. Our study aims to assess and compare the humoral response in heterogeneous population based on infection and vaccination status along with hybrid immunity. Methods A retrospective, observational study of 2,545 adults was conducted. The study groups comprised of group I (n = 309) naive with a single dose of vaccination, group II (n = 357) infected and unvaccinated, group III (n = 590) completely vaccinated with two doses of vaccine, group IV (n = 70) booster dose, group V (n = 602) with hybrid immunity (pre-vaccination infection), and group VI (n = 617) with breakthrough infection (post-vaccination infection). Data pertaining to demographic details, clinical presentations, reverse transcription-polymerase chain reaction, anti-SARS-CoV-2 total antibodies immunoglobulin G (IgG), neutralizing antibodies by anti SARS-CoV-2 sVNT (surrogate virus neutralization test), S1/S2IgG, S-RBD (receptor-binding domain), and ChAdOx1-nCov-19 (Covishield) vaccination were retrieved from electronic health records. Results The mean levels of neutralizing antibodies of group V were S1/S2, RBD (10.5/14.3 times), and sVNT (84.44%) and group VI had S1/S2, RBD (11.4/11.8 times), and sVNT (78.07%) when compared to group III. We also observed a statistically significant higher immune response in group V and VI than group I and II. A higher percentage (18.2%) of group II individuals had severe disease when compared to group V and VI (6.5/10.8%). Conclusion A single dose of ChAdOx1 vaccine gives robust antibody responses in previously infected individuals and may confer long-term hybrid immunity following booster vaccination.